The European Union should renegotiate a 1 billion euro ($1.2 billion) contract it sealed last week with Gilead for a six-month supply of the COVID-19 drug remdesivir after it showed poor results in a large trial, experts said on Friday.
In a blow to one of the few drugs being used to treat people with Covid-19, the Solidarity Trial conducted by the World Health Organisation showed that remdesivir appeared to have little or no effect on mortality or length of hospital stays among patients with the respiratory disease.
